• Ascletis selected an oral, once-daily fixed-dose combination of ASC48 and ASC30 for clinical development in obesity.
• U.S. FDA IND submission for ASC30_48 oral tablets is expected in Q4 2026.
• In a head-to-head non-human primate study, ASC30_48 cut body weight 10.5% vs 6.9% for ASC30 alone over eight days.
• ASC48 showed 1 pM EC50 in a human GIPR cAMP assay vs 3 pM for tirzepatide, supporting a dual GLP-1R/GIPR oral program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN05063) on July 15, 2026, and is solely responsible for the information contained therein.